Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility study of post-SBRT adjuvant tegafur-uracil in stage I NSCLC
jRCT1091220068Unknown
- Sponsor
- Kinji Nishiyama
- Start
- Jul 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tegafur + uracil in non-small cell lung cancer (NSCLC), sponsored by Kinji Nishiyama. Primary endpoint: feasibility. Status: unknown.
02
Drugs
tegafur + uracil
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1091220068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220068.